ADLAI NORTYE LTD

ADLAI CFO Ye Xiaofeng sells 12,667 ADS for tax‑planning, not strategy. 12‑month outlook focuses on clinical milestones and regulatory approvals, not insider trading.

Adlai Nortye’s CEO sells 10 ADS after a price dip— a modest move that could signal short‑term caution, but doesn’t alter the company’s biopharma pipeline or long‑term strategy.

Adlai Nortye insiders boost long‑term value: CEO Lu Yang acquires 16.99 m Class B shares and RSUs, signaling confidence as the biotech eyes upcoming clinical milestones.

Adlai Nortye insider filings reveal long‑term confidence amid explosive 680 % revenue growth, a pending closed‑trading window, and key clinical milestones that could drive future value.